Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population

Journal of Infectious Diseases

Volumn 187, Issue 4, 2003, Pages 683-686

  Leigh Brown, Andrew J ^a,f   Frost, Simon D W ^a   Mathews, W Christopher ^b   Dawson, Keith ^c   Hellmann, Nicholas S ^c   Daar, Eric S ^d   Richman, Douglas D ^a,b,e   Little, Susan J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c MONOGRAM BIOSCIENCES   (United States)

^d HARBOR UCLA MEDICAL CENTER   (United States)

^e VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG RESPONSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS STRAIN; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; NORTH AMERICA; RETROSPECTIVE STUDIES; TREATMENT FAILURE; URBAN POPULATION; VIRAL LOAD;

EID: 0037443126     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/367989     Document Type: Article

References (18)

1. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000; 287:650-4.
2. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-94.
3. Palella FJJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
4. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-9.
5. Leigh Brown AJ, Precious HM, Whitcomb JM, et al. Reduced susceptibility of HIV-1 from patients with primary HIV infection to non-nucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites. J Virol 2000; 74:10269-73.
6. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society - USA Panel. JAMA 2000; 283:2417-26.
7. Bozzette SA, Berry SH, Duan N, et al. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med 1998; 339:1897-904.
8. Richman D, Bozzette S, Morton S, et al. The prevalence of antiretroviral drug resistance in the US [abstract]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
9. Goudsmit J, de Ronde A, Ho DD, Perelson AS. Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase. J Virol 1996; 70:5662-4.
10. Garcia-Lerma JG, Nidtha S, Blumoff K, Weinstock H, Heneine W. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc Natl Acad Sci USA 2001; 98:13907-12.
11. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54.
12. Leigh Brown AJ, Frost SDW, McLean A, et al. Transmission fitness of drug resistant strains. Antivir Ther 2000; 5(Suppl 3):143.
13. Colfax GN, Buchbinder SP, Cornelisse PG, Vittinghoff E, Mayer K, Celum C. Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS 2002; 16:1529-35.
14. Havlir DV, Eastman S, Gamst A, Richman DD. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol 1996; 70:7894-9.
15. Eastman PS, Mittler J, Kelso R, et al. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy. J Virol 1998; 72:5154-64.
16. Wrin T, Gamarnik A, Whitehurst N, et al. Natural variation of replicative capacity measurements in drug-naive/susceptible HIV-1. Antivir Ther 2001; 6(Suppl 1):20.
17. Eron JJ, Vernazza PL, Johnston DM et al. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS 1998; 12:F181-9.
18. Taylor S, van Heeswijk RP, Hoetelmans RM, et al. Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men. AIDS 2000; 14:1979-84.